Efavirenz therapy in drug users

HIV Medicine

Volumn 1, Issue SUPPL. 1, 2000, Pages 15-17

  Clarke, S M ^a   Mulcahy, F M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HIV AGENTS; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; METHADONE; NARCOTIC ANALGESIC AGENT; OXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADDICTION; DRUG COMBINATION; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMAN; METHADONE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 18044404515     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00004.x     Document Type: Article

References (23)

1. Chesney M, Ickovics JM, Hecht F, et al. Adherence: a necessity for successful HIV combination therapy. AIDS 1999; 13 (Suppl. A): S271-S278.
2. Deeks SG, Loftus R, Beatty G, et al. Incidence and predictors of virological failure of indinavir or ritonavir in an urban AIDS clinic. International Conference on Antimicrobial Agents and Chemotherapy, Toronto, October 1997; abstract.
3. BHIVA: Writing committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIVMed 2000; 1: 76-101.
4. Carpenter CC, Cooper DA, Fischyl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society USA panel. JAMA 2000; 19: 381-390.
5. Turner JG, Nokes KM, Corless IB, etal. History of drug use and adherence in HFV positive infected persons. XII International Conference on AIDS, Geneva, June 1998; abstract 32366.
6. Strathdee SA, Palepu A, Cornelisse PGA, etal. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1988; 280: 547-549.
7. Clarke S, Harrington P, Forkin C, Curran S, Keenan E, Mulcahy F. BHIVA Spring meeting. DAART- a one year review. 6th Annual Conference of the British HIV Association (BHIVA), Edinburgh, March 2000; 7 abstract P2.
8. Adkins JC, Noble S. Efavirenz. Drugs 1998; 56: 1055-1064.
9. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate versus high dose methadone in the treatment of opiate dependence. JAMA 1999; 281: 1000-1005.
10. Olsen CD, Wendel HA, Livermore JD, étal. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pliarmacol Ther 1998; 21: 147-157.
11. Scott CC, Robbins EB, Chen KK. Pharmacological comparison of the optical isomers of methadone. J Pliarmacol Exp Ther 1997; 92: 282-286.
12. Iribarne C, Berthou F, Baird S, eraJ. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Client Res Tori'co/ 1996; 9: 365-373.
13. Sullivan HK, Due SL, McMahon RE. Methadone N-oxide in the urine of methadone maintained subjects. J Pharm Pliarmacol 1973; 25: 1009-1010.
14. Cobb MN, Rpa C, Desai J, Brown LS, Zannikos PN, Rainey PM. The effects of fluconazole on the clinical pharmacokinetics of methadone. Clin Pliarmacol Ther 1998; 63: 655-662.
15. Tong TG, Pond SM, Kreek MJ. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981; 94: 349-351.
16. Saxon AJ, VVhittacker S, Hawker S. Valproic acid-inlike other anticonvulsants has no effect on methadone metabolism: 2 cases. J Clin Psychol 1989; 50: 228-229.
17. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampicininduccd methadone withdrawal. N Engt J Med 1976; 294: 1104-1106.
18. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med 1984; 144: 1671-1667.
19. Raistrick D, Hay A, Wolff K. Methadone maintenance and tuberculosis treatment. Br Med J 1996; 313: 925-926.
20. Holmes VF. Rifampicin induced methadone in AIDS. J Clin Psychopharinacol 1990; 10: 443-444.
21. Clarke S, Mulcahy F, Back DJ, etal. Managing methadone and non-nucleoside reverse transcriptase inhibitors. Guidelines for clinical practice. 7th Conference on Retroi'iruses and Opportunistic Infections, San Francisco, 1999; abstract 88.
22. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pliarmacokinet 1997; 32: 210-258.
23. Wilkinson GR, Shand DGA. Physiological approach to hepatic drug clearance. Clin Pliarmacol Ther 1975; 18: 377-390.